melanoma

January 11, 2021January 11, 2021

Personalized AV-GBM-1 Vaccine Shows Promise for Aggressive Brain Cancer

News

Adding AIVITA Biomedical’s experimental and personalized cancer vaccine, AV-GBM-1, to post-surgery standard treatment slows disease progression in adults newly diagnosed with glioblastoma — the most aggressive type of brain cancer ... Read more

December 21, 2020December 21, 2020

Cancer Vaccines Get FDA Breakthrough Status in Advanced Melanoma Combo Therapy

News

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s lead anti-cancer vaccine candidates IO102 and IO103, plus an ... Read more

August 3, 2020August 3, 2020

FDA Approves Tecentriq Combo for Certain Advanced Melanomas

News

The U.S. Food and Drug Administration (FDA) has approved the immunotherapy Tecentriq (atezolizumab), in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive advanced melanoma. The ... Read more

July 30, 2019August 26, 2019

ONCOS-102, Keytruda Combo May Reduce Tumor Size in Treatment-resistant Melanoma, Early Trial Data Show

News

Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is testing ... Read more

July 24, 2019

First Melanoma Patient Dosed with Syntrix’ SX-682 in Combo with Keytruda in Phase 1/2 Trial

News

Syntrix Pharmaceuticals has dosed the first patient in an ongoing Phase 1/2 clinical trial testing its experimental therapy SX-682 in combination with Keytruda (pembrolizumab) as a treatment for advanced melanoma, the ... Read more

July 23, 2019

PrimeVax Receives FDA’s OK to Use Dengue Virus for Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) has approved three clinical studies testing PrimeVax Immuno-Oncology’s investigational approach using dendritic cells and dengue virus for cancer treatment. The investigational new drug ... Read more

July 16, 2019

FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule

News

The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication can ... Read more

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

News

Immunophotonics and Clinical Laserthermia Systems (CLS) are teaming up in a Phase 1/2 trial to explore the safety and effectiveness of a thermal ablation approach — destruction of tissue by ... Read more

April 24, 2019

Aprea’s APR-246 Stabilizes Key Tumor Suppressor Protein and Boosts Immune Responses in Mouse Study

News

Aprea Therapeutics‘ APR-246 stabilizes the tumor suppressor protein p53, boosting responses to checkpoint blockade immunotherapies in mouse models of melanoma and colorectal cancer, a study says. Findings were announced in ... Read more

April 23, 2019

Melanomas with NF-kB Activation Are Easier to Target with Immune Checkpoint Inhibitors, Study Says

News

Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about three ... Read more